Key clinical point: Bone-targeted α-emitting radioisotopes (radium-223) significantly improve survival in patients with metastatic castration-resistant prostate cancer (CRPC) but not β-emitting radioisotopes (strontium-89).

Major finding: α-emitting radioisotopes were significantly associated with an overall survival benefit (hazard ratio [HR], 0.70; 95% CI, 0.58-0.83), but β-emitting radioisotopes (strontium-89) were not associated with any overall survival benefit (HR, 0.96; 95% CI, 0.84-1.10).

Study details: Meta-analysis of individual patient data from 6 randomized studies including 2,081 patients with metastatic CRPC.

Disclosures: The study was funded by Bayer and Ligue Nationale Contre le Cancer. Several authors reported receiving grants and personal fees from multiple pharmaceutical companies, including Bayer.